Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,394 | 0,474 | 27.03. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
20.03. | ABBISKO-B (02256): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | 1 | HKEx | ||
20.03. | ABBISKO-B (02256): NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | 1 | HKEx | ||
20.03. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
13.03. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
13.03. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE | 1 | HKEx | ||
12.03. | ABBISKO-B (02256): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 AND PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ... | 1 | HKEx | ||
28.02. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS DELIVERED ORAL PRESENTATION OF PRELIMINARY FIRST-IN-HUMAN TRIAL RESULTS OF ITS HIGHLY ... | 1 | HKEx | ||
26.02. | ABBISKO-B (02256): DATE OF BOARD MEETING | - | HKEx | ||
23.02. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT DOSE OF NEXT-GENERATION EGFR EXON20INS INHIBITOR ABSK112 COMPLETED BY ABBISKO THERAPEUTICS | 1 | HKEx | ||
06.02. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS RECEIVED UPFRONT PAYMENT UPON THE ENTRY INTO A LICENSING AGREEMENT FOR PIMICOTINIB (ABSK021) ... | 1 | HKEx | ||
01.02. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO THE POST-IPO RSU SCHEME | 1 | HKEx | ||
10.01. | Abbisko Therapeutics' Cancer Drug Gets EU's Orphan Drug Label | 3 | Yicai Global | ||
09.01. | Abbisko Therapeutic announces that EMA has granted orphan drug designation for its CSF-1R inhibitor Pimicotinib (ABSK021) | 324 | PR Newswire | SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- On January 9, 2024 (Beijing Time), Abbisko Therapeutics (HKEX code: 02256) announced that its investigational innovative CSF-1R inhibitor pimicotinib(ABSK021)... ► Artikel lesen | |
09.01. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - CSF-1R INHIBITOR PIMICOTINIB GRANTED ODD BY EMA | 1 | HKEx | ||
03.01. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - CD73 INHIBITOR ABSK051 COMPLETED THE FIRST PATIENT DOSE | 1 | HKEx | ||
14.12.23 | Abbisko tenosynovial giant cell tumour therapy gains fast track status | 2 | Pharmaceutical Technology | ||
14.12.23 | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - CSF-1R INHIBITOR PIMICOTINIB (ABSK021) GRANTED FAST TRACK DESIGNATION BY U.S. FDA | 2 | HKEx | ||
12.12.23 | HSBC raises Abbisko (02256) to HKD6.2 | 1 | etnet | ||
06.12.23 | Merck gains rights to Abbisko's pimicotinib in deal worth over $70m | 11 | PMLiVE |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 39,350 | +0,03 % | Rheinmetall, Vonovia, Munich Re, Qiagen: DAX-Überblick | Der DAX (WKN: 846900) ist weiterhin nicht zu bremsen. Am Dienstag legte das größte deutsche Börsenbarometer knapp 140 Punkte zu und ging +0,54% höher mit 18.399 Punkten aus dem Handel. Gefragt waren... ► Artikel lesen | |
EVOTEC | 14,455 | +0,56 % | Übernahmen im BioTech-Sektor! Nach MorphoSys könnten Evotec, Medigene oder sogar Bayer folgen! | Im Jahr 2022 erhielten insgesamt 18,5 Mio. Menschen die schockierende Diagnose "Krebs". Aktuelle Trends sprechen leider dafür, dass diese Zahl in den nächsten Jahren nicht kleiner wird. Dank wachsender... ► Artikel lesen | |
IBIO | 3,650 | 0,00 % | Pre-market Movers: iBio, Direct Digital Holdings, Nuvation Bio, PaySign, LuxUrban Hotels | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 07.30 A.M. ET).In the Green iBio, Inc. (IBIO) is up over 86% at $2.14.
Nuvation... ► Artikel lesen | |
MORPHOSYS | 67,20 | 0,00 % | Morphosys mit EILMELDUNG: Experte setzt BRANDNEUES Kursziel - Sofortiges HANDELN erforderlich! | ||
ANNEXON | 7,980 | 0,00 % | Annexon Biosciences: Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones | Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024 Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in Geographic Atrophy (GA) Expected in mid-2024... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 10,240 | 0,00 % | Recursion Pharmaceuticals: Recursion Publishes Annual Environmental, Social and Governance Report | ||
4D MOLECULAR THERAPEUTICS | 35,710 | 0,00 % | 4D Molecular Therapeutics, Inc.: 4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis | ||
PRAXIS PRECISION MEDICINES | 59,19 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients | In the 45 mg cohort, 100% of patients achieved a complete response In the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a partial response Safety was consistent with... ► Artikel lesen | |
IMMUNOVANT | 32,310 | 0,00 % | Pre-market Movers: Kaival Brands, Lufax Holding, Tourmaline Bio, Laser Photonics Corporation, Immunovant | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.00 A.M. ET).In the Green Kaival Brands Innovations Group... ► Artikel lesen | |
DYNE THERAPEUTICS | 28,460 | 0,00 % | Dyne Therapeutics Appoints John Cox As CEO To Succeed Joshua Brumm | WASHINGTON (dpa-AFX) - Dyne Therapeutics, Inc. (DYN) said on Monday that it has appointed John Cox as Chief Executive Officer with immediate effect to succeed Joshua Brumm, who has decided to... ► Artikel lesen | |
BIONTECH | 86,20 | +0,30 % | BioNTech unter Druck: Jetzt fallen auch die Kursziele | Das Mainzer Biotech-Unternehmen BioNTech hat am Mittwoch seine Zahlen für das vergangene Geschäftsjahr vorgelegt. Anleger hatten mehr erhofft, die Aktie knickte teilweise deutlich ein, am Ende ging... ► Artikel lesen | |
ADMA BIOLOGICS | 6,725 | 0,00 % | A Closer Look at 6 Analyst Recommendations For ADMA Biologics | ||
AVIDITY BIOSCIENCES | 24,250 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, March 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 49,680 | 0,00 % | Ascendis Pharma and MoonLake Immunotherapeutics dropped from Wedbush list | ||
AEROVATE THERAPEUTICS | 28,790 | 0,00 % | Aerovate Therapeutics, Inc.: Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights | Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) Completed enrollment in the Phase... ► Artikel lesen |